 |
|
|
| |
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MK-1439, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects
|
| |
| |
Reported by Jules Levn
CROI 2013
Matt S. Anderson1, Jocelyn Gilmartin1, Caroline Cilissen2, Inge De Lepeleire2, Luc van Bortel3, Marissa Fallon Dockendorf1, Ernestina Tetteh1, Ying Guo1, John A. Wagner1, Joan R. Butterton1
Merck, 1Whitehouse Station, NJ and MSD 2Brussels, Belgium; 3Drug Research Unit Ghent, Belgium
CROI: Safety and Antiviral Activity of MK-1439, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), In Treatment-Naïve HIV-Infected Patients - (03/05/13)
|
| |
|
|
|
|
|
